All articles tagged with #triple negative
AstraZeneca and Gilead Sciences presented successful trial results for antibody-drug conjugates as new first-line treatments for metastatic triple-negative breast cancer, offering potential options after over a decade without new approvals for this aggressive cancer type.
Misty De La Cruz, a mother battling stage three triple-negative breast cancer with a 20% survival chance, faces not only her health challenges but also the emotional toll on her children, especially after her son's heartbreaking fear of losing her. Her diagnosis, treatment, and genetic mutation highlight the rising incidence of breast cancer among younger women, emphasizing the importance of regular self-exams and early detection.
A new vaccine trial for patients with triple-negative breast cancer has shown promising results, with an 88% survival rate after three years. Conducted by Washington University School of Medicine, the trial involved 18 patients who received a personalized neoantigen DNA vaccine alongside standard care. The vaccine was well-tolerated and stimulated immune responses in most patients, with 16 remaining cancer-free after three years. Although the trial lacked a control group, historical data suggests the vaccine may significantly improve outcomes compared to standard treatments alone. Further randomized controlled trials are underway to confirm these findings.